On this page
DFNA9 (progressive, COCH)
This rare genetic condition leads to gradual worsening of hearing, often accompanied by balance difficulties. Symptoms typically emerge between the third and fifth decades of life, progressing over time to severe hearing impairment in many affected individuals.
Overview
DFNA9 represents a specific type of autosomal dominant non-syndromic hearing loss, meaning it affects hearing without involving other body systems in a pattern suggesting a broader syndrome. The condition takes its name from the classification system for dominant hearing loss (DFNA stands for deafness, autosomal dominant) and is caused by pathogenic variants in COCH. Unlike congenital hearing loss present from birth, DFNA9 typically manifests during adulthood, with most affected individuals noticing hearing difficulties between ages 20 and 50 years.
The condition is characterised by progressive sensorineural hearing loss, meaning the problem arises from damage to the inner ear structures or the auditory nerve rather than mechanical issues in the outer or middle ear. Many individuals also experience vestibular symptoms affecting balance and spatial orientation. The rate of progression varies between families and even among affected members of the same family, though hearing typically worsens over years to decades. DFNA9 is considered rare, with exact prevalence figures not well established in the UK population.
Symptoms & clinical features
The hallmark feature of DFNA9 is gradual hearing loss that worsens over time. Initially, individuals may notice difficulty hearing high-pitched sounds or understanding speech in noisy environments. As the condition progresses, lower frequencies become affected, eventually leading to profound hearing loss in many cases. The hearing loss is typically bilateral, affecting both ears, though the severity may differ slightly between sides.
Balance problems represent another important feature, often preceding or accompanying the hearing difficulties. Affected individuals may experience episodes of vertigo (a spinning sensation), unsteadiness whilst walking, or difficulty maintaining balance in low-light conditions. Some people report a sensation of fullness in the ears or tinnitus (ringing or buzzing sounds). The vestibular symptoms can significantly impact daily activities and quality of life, particularly as they often persist or worsen alongside the hearing loss.
Video: Genetics 101
Affected organs
DFNA9 primarily affects the inner ear, specifically the cochlea (responsible for hearing) and the vestibular system (responsible for balance and spatial orientation). The cochlea contains specialised sensory hair cells that convert sound vibrations into electrical signals transmitted to the brain. In DFNA9, abnormal protein deposits accumulate within the inner ear structures, disrupting normal function and leading to progressive degeneration of these delicate sensory cells.
The vestibular organs, including the semicircular canals and otolith organs, are similarly affected by protein accumulation. This explains why balance difficulties often accompany the hearing loss in this condition. The auditory nerve, which carries signals from the inner ear to the brain, may also be affected as the condition progresses.
Risks & severity
The severity of DFNA9 varies considerably, even within the same family. Most affected individuals develop noticeable hearing loss between ages 20 and 50 years, though onset outside this range has been documented. Progression is generally relentless, with many people experiencing severe to profound hearing loss by their fifth or sixth decade of life. The rate of decline differs; some individuals maintain useful hearing for longer periods, whilst others progress more rapidly.
Vestibular symptoms can be equally variable in severity. Some people experience only mild, occasional balance difficulties, whilst others develop persistent problems requiring walking aids or lifestyle modifications. The unpredictability of disease progression makes counselling challenging, though observing the pattern within a family can sometimes provide clues about likely trajectory. There is no established correlation between the age of onset and the rate of progression.
Genetic causes
DFNA9 is caused by pathogenic variants in COCH, which provides instructions for producing cochlin, an extracellular matrix protein abundantly expressed in the inner ear. Cochlin normally contributes to the structural integrity of inner ear tissues and may play a role in the body's immune response within these structures. The protein is particularly concentrated in areas critical for hearing and balance function.
Pathogenic variants in COCH typically result in the production of an abnormal cochlin protein that misfolds and aggregates. Rather than being cleared from cells normally, these abnormal proteins accumulate as deposits within the inner ear, a process somewhat analogous to the protein accumulation seen in other degenerative conditions. These deposits disrupt the delicate architecture of the cochlea and vestibular organs, leading to progressive loss of sensory cells and declining function. Most pathogenic variants cluster in specific regions of the gene, and the same variant may produce different clinical severity in different individuals, suggesting that additional genetic or environmental factors influence disease expression.
- COCH cochlin
Inheritance pattern
DFNA9 follows an autosomal dominant inheritance pattern, meaning a single pathogenic variant in one copy of COCH is sufficient to cause the condition. Each child of an affected individual has a 50% chance of inheriting the pathogenic variant and developing hearing loss. The condition affects males and females equally and can be passed down through multiple generations.
Because symptoms typically begin in adulthood, individuals may have children before knowing they carry a pathogenic variant. Family history often reveals multiple affected relatives across generations, though the age of onset and severity may differ among family members. Genetic counselling can help families understand inheritance risks and discuss options such as predictive testing for at-risk relatives or reproductive choices for those who carry a pathogenic variant.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of DFNA9 combines clinical evaluation with genetic testing. Initial assessment typically includes detailed hearing tests (audiometry) demonstrating the characteristic pattern of progressive sensorineural hearing loss, along with vestibular function testing to assess balance. The presence of similar symptoms in family members across generations supports a genetic cause.
Genetic testing through NHS laboratories can identify pathogenic variants in COCH, confirming the diagnosis. Testing is usually arranged through clinical genetics services following referral from an ear, nose and throat specialist or audiologist. In England, DFNA9 falls under the NHS Genomic Medicine Service pathway for hearing loss, with COCH included on the relevant gene panels. A confirmed genetic diagnosis allows for cascade testing of at-risk family members and provides certainty about the underlying cause, which can be valuable for management planning and family counselling.
Management & lifestyle
Management of DFNA9 focuses on optimising hearing and addressing balance difficulties, as no treatment currently exists to prevent or reverse the underlying genetic cause. Hearing aids represent the mainstay of support for those with mild to moderate hearing loss, and cochlear implantation may be considered when hearing loss becomes severe or profound. Regular audiological follow-up allows hearing support to be adjusted as the condition progresses.
Balance rehabilitation through vestibular physiotherapy can help individuals develop compensatory strategies and reduce fall risk. Some people benefit from walking aids or modifications to their home environment. Genetic counselling provides affected individuals and their families with information about inheritance, reproductive options, and predictive testing for relatives. The NHS care pathway typically involves coordinated input from audiology, ENT specialists, clinical genetics and rehabilitation services to address the multiple aspects of this condition.
UK care pathway
In the UK, individuals with suspected DFNA9 are typically referred to audiology services for detailed hearing assessment and to ENT specialists for clinical evaluation. Where a genetic cause is suspected based on family history or clinical pattern, referral to clinical genetics services allows access to genetic testing through the NHS Genomic Medicine Service. COCH is included on the hearing loss gene panel (PanelApp), enabling testing within the standard genomic medicine pathway.
Following a genetic diagnosis, affected individuals and their families can access genetic counselling to discuss inheritance, family planning options, and testing for at-risk relatives. Long-term management involves ongoing monitoring through audiology and ENT services, with access to hearing technology and vestibular rehabilitation as needed. Care is typically coordinated locally, with input from multiple specialties to address both the hearing and balance aspects of the condition.
Frequently asked questions
Will my hearing loss definitely get worse over time?
Research suggests that DFNA9 typically causes progressive hearing loss, meaning it worsens over years to decades. However, the rate of progression varies considerably between individuals, and predicting the exact trajectory for any one person remains challenging.
Can anything be done to slow down the hearing loss?
Currently, no treatments are known to slow or prevent progression of DFNA9. Management focuses on maximising hearing through aids or cochlear implants and addressing balance problems through rehabilitation. Research into therapies targeting the underlying protein accumulation continues.
Should my children be tested for the COCH variant?
This is a personal decision best discussed with a genetic counsellor. Because symptoms typically don't appear until adulthood, some families choose to wait until children are old enough to decide for themselves whether they want predictive testing, whilst others prefer testing earlier. There is no medical urgency for testing in childhood.
Will I definitely need a cochlear implant eventually?
Not everyone with DFNA9 progresses to the degree of hearing loss where cochlear implantation is needed or beneficial. Many people manage well with hearing aids for extended periods. If hearing loss does become severe or profound, cochlear implants can be effective and are considered when appropriate by audiology specialists.